The Genotypic False Positive Rate Determined by V3 Population Sequencing Can Predict the Burden of HIV-1 CXCR4-using Species Detected by Pyrosequencing

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Svicher, Valentina ^a   Cento, Valeria ^a   Rozera, Gabriella ^b   Abbate, Isabella ^b   Santoro, Maria Mercedes ^a   Armenia, Daniele ^a   Fabeni, Lavinia ^b   Bruselles, Alessandro ^b   Latini, Alessandra ^c   Palamara, Guido ^c   Micheli, Valeria ^d   Rizzardini, Giuliano ^d   Gori, Caterina ^b   Forbici, Federica ^b   Ippolito, Giuseppe ^b   Andreoni, Massimo ^e   Antinori, Andrea ^b   Ceccherini Silberstein, Francesca ^a   Capobianchi, Maria Rosaria ^b   Perno, Carlo Federico ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; MARAVIROC; VIRUS RNA;

ADULT; ARTICLE; CLINICAL PRACTICE; CORRELATION ANALYSIS; FALSE POSITIVE RESULT; FEMALE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PYROSEQUENCING; SEQUENCE ANALYSIS; ULTRA DEEP PYROSEQUENCING; VIRAL GENETICS; VIRAL TROPISM;

ADULT; BASE SEQUENCE; FALSE POSITIVE REACTIONS; FEMALE; GENETIC VARIATION; GENOTYPE; GENOTYPING TECHNIQUES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MALE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CXCR4; SEQUENCE ANALYSIS, DNA; TEMPERATURE; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872364157     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053603     Document Type: Article

References (28)

1. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, et al. (1998) A new classification for HIV-1. Nature 391: 240. 10.1038/34571 [doi].
2. Regoes RR, Bonhoeffer S (2005) The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13: 269-277. S0966-842X(05)00110-1 [pii];10.1016/j.tim.2005.04.005 [doi].
3. Waters L, Mandalia S, Randell P, Wildfire A, Gazzard B, et al. (2008) The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 46: 1617-1623. 10.1086/587660 [doi].
4. Raymond S, Delobel P, Mavigner M, Cazabat M, Encinas S, et al. (2010) CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 24: 2305-2312. 10.1097/QAD.0b013e32833e50bb [doi].
5. Macarthur RD, Novak RM (2008) Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 47: 236-241. 10.1086/589289 [doi].
6. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vezinet F, Clotet B, et al. (2011) European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 11: 394-407. S1473-3099(10)70319-4 [pii];10.1016/S1473-3099(10)70319-4 [doi].
7. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, et al. (2007) Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 23: 415-426. 10.1089/aid.2006.0130 [doi].
8. Hoffman TL, Doms RW, (1999) HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol Membr Biol 16: 57-65.
9. Nolan KM, Jordan AP, Hoxie JA (2008) Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J Virol 82: 664-673. JVI.01793-07 [pii];10.1128/JVI.01793-07 [doi].
10. Abbate I, Vlassi C, Rozera G, Bruselles A, Bartolini B, et al. (2011) Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 25: 611-617. 10.1097/QAD.0b013e328343489e [doi].
11. Abbate I, Rozera G, Giombini E, D'Offizi G, Nicastri E, et al. (2011) Deep Sequencing of Plasma and Proviral HIV-1 to Establish Coreceptor Usage: What Is the Clinical Impact of the Quasispecies Distribution? J Infect Dis 204: 971-973. jir427 [pii];10.1093/infdis/jir427 [doi].
12. Abbate I, Rozera G, Tommasi C, Bruselles A, Bartolini B, et al. (2011) Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment. Clin Microbiol Infect 17: 725-731. CLM3350 [pii];10.1111/j.1469-0691.2010.03350.x [doi].
13. Chueca N, Garrido C, Alvarez M, Poveda E, de Dios LJ, et al. (2009) Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol 81: 763-767. 10.1002/jmv.21425 [doi].
14. Harrigan R, Zhong X, Lewis M, Dong W, Knapp D, et al. (2010) The influence of PCR amplification variation on the ability of population-based PCR to detect non-R5 HIV. Rewievs in Antiviral Therapy & Infectious Diseases, Abstract Book of 8th European HIV Drug Resistance Workshop 1: 36-37.
15. McGovern RA, Harrigan PR, Swenson LC (2010) Genotypic inference of HIV-1 tropism using population-based sequencing of V3. J Vis Exp. 2531 [pii];10.3791/2531 [doi].
16. Poveda E, Seclen E, Gonzalez MM, Garcia F, Chueca N, et al. (2009) Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 63: 1006-1010. dkp063 [pii];10.1093/jac/dkp063 [doi].
17. Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, et al. (2009) Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 6: 15. 1742-4690-6-15 [pii];10.1186/1742-4690-6-15 [doi].
18. Svicher V, D'Arrigo R, Alteri C, Andreoni M, Angarano G, et al. (2010) Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol 33: 195-206.
19. Svicher V, Balestra E, Cento V, Sarmati L, Dori L, et al. (2011) HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res 90: 42-53. S0166-3542(11)00033-7 [pii];10.1016/j.antiviral.2011.02.005 [doi].
20. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 203: 237-245. jiq030 [pii];10.1093/infdis/jiq030 [doi].
21. Saliou A, Delobel P, Dubois M, Nicot F, Raymond S, et al. (2011) Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 55: 2831-2836. AAC.00091-11 [pii];10.1128/AAC.00091-11 [doi].
22. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, et al. (2008) Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22: F11-F16. 10.1097/QAD.0b013e32830ebcd4 [doi].
23. Boyd MT, Simpson GR, Cann AJ, Johnson MA, Weiss RA, (1993) A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J Virol 67: 3649-3652.
24. Dimonte S, Mercurio F, Svicher V, D'Arrigo R, Perno CF, et al. (2011) Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v(3) signatures in the regulation of co-receptor usage. Retrovirology 8: 33. 1742-4690-8-33 [pii];10.1186/1742-4690-8-33 [doi].
25. Fouchier RA, Brouwer M, Broersen SM, Schuitemaker H, (1995) Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 33: 906-911.
26. Koito A, Stamatatos L, Cheng-Mayer C (1995) Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 206: 878-884. S0042-6822(85)71010-0 [pii];10.1006/viro.1995.1010 [doi].
27. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, et al. (2006) Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol 80: 750-758. 80/2/750 [pii];10.1128/JVI.80.2.750-758.2006 [doi].
28. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 53: 732-742. cir493 [pii];10.1093/cid/cir493 [doi].